This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zymeworks (ZYME) Surges 7.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
Zymeworks (ZYME) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
All You Need to Know About Zymeworks (ZYME) Rating Upgrade to Buy
by Zacks Equity Research
Zymeworks (ZYME) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts See a 76.74% Upside in Zymeworks (ZYME): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 76.7% upside potential for Zymeworks (ZYME). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Think Zymeworks (ZYME) Could Surge 83.89%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at an 83.9% upside potential for Zymeworks (ZYME). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zymeworks Inc. (ZYME) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Zymeworks (ZYME) delivered earnings and revenue surprises of 33.33% and 57.36%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Zymeworks (ZYME) Soars 5.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Zymeworks (ZYME) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zymeworks Inc. (ZYME) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Zymeworks (ZYME) delivered earnings and revenue surprises of 3.12% and 15.54%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Compugen (CGEN) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Compugen (CGEN) delivered earnings and revenue surprises of -200% and 91.58%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Apellis Pharmaceuticals (APLS) delivered earnings and revenue surprises of 25.64% and 8.46%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
PTC Therapeutics (PTCT) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of 75% and 3.96%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 11.54% and 2.23%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Believe Zymeworks (ZYME) Could Rally 41.36%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Zymeworks (ZYME) points to a 41.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zymeworks Inc. (ZYME) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Zymeworks (ZYME) delivered earnings and revenue surprises of 2.50% and 12.98%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
GSK (GSK) Q3 Earnings Surpass Estimates
by Zacks Equity Research
Glaxo (GSK) delivered earnings and revenue surprises of 9.48% and 2.16%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Zymeworks Inc. (ZYME) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Zymeworks (ZYME) delivered earnings and revenue surprises of 3.70% and 16.93%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
AnaptysBio (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Zymeworks (ZYME) delivered earnings and revenue surprises of -35.48% and 44.22%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
3 Top Stocks to Invest in for Amazing Earnings Acceleration
by Tirthankar Chakraborty
Invest in companies such as Zymeworks (ZYME), Evolus (EOLS) and Bilibili (BILI) for superb earnings acceleration.
Zymeworks (ZYME) Loses -13.41% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Zymeworks (ZYME) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Zymeworks (ZYME) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Zymeworks (ZYME) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zymeworks Inc. (ZYME) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 48.72% and 7.59%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Will EyePoint Pharmaceuticals (EYPT) Report Negative Q4 Earnings? What You Should Know
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Zymeworks Inc. (ZYME) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MannKind (MNKD) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
MannKind (MNKD) delivered earnings and revenue surprises of 300% and 11.67%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Zymeworks Inc. (ZYME) Is Up 1.64% in One Week: What You Should Know
by Zacks Equity Research
Does Zymeworks Inc. (ZYME) have what it takes to be a top stock pick for momentum investors? Let's find out.